Company
Lexicon Pharmaceuticals, Inc.
Headquarters: The Woodlands, TX, United States
Founded: The Woodlands, TX, 1995
Employees: 87
CEO: Mr. Lonnel Coats
Market Cap
$320.0 Million
USD as of Jan. 1, 2025
Lexicon Pharmaceuticals, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $2.3 M |
| EBITDA | $-185,360,496 |
| Gross Profit TTM | $1.1 M |
| Profit Margin | 92.94% |
| Operating Margin | -4011.77% |
| Quarterly Revenue Growth | 4608.30% |
Stocks & Indices
Lexicon Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: LXRX wb_incandescent
Stock: FSX: LX31 wb_incandescent
Key People
Lonnel Coats, president and chief executive officer Brian P. Zambrowicz, E VP & Chief Scientific Officer Jeffrey L. Wade, E VP of Corporate Development & Chief Scientific Officer Alan J. Main, E VP of Pharmaceutical Research Pablo Lapuerta, E VP of Clinical Development & Chief Medical Officer James F. Tessmer, VP of Finance and Accounting